HDAC6 and susceptibility to pneumonia measurement: The combination of ACY-241 with nivolumab (anti-PD-L1 antibody) was shown to cause side effects such as dyspenia (1/17) and pneumonia (2/17) in patients with NSCLCs who had not received an HDAC6 inhibitor or immune checkpoint inhibitor (n = 17) [161].